Table 2.
Overall cohort |
Approximate Quartile of MIND Diet | ||||
---|---|---|---|---|---|
Q1 | Q2 | Q3 | Q4 | ||
N | 180 | 49 | 52 | 39 | 40 |
Mean (SD)* | 8.46 (1.45) | 6.49 (1.03) | 8.29 (0.25) | 9.28 (0.25) | 10.68 (0.81) |
Median (range)* | 8.5 (4.00–12.00) | 7 (6–7) | 8.5 (8–8.5) | 9.5 (9–9.5) | 10.5 (10–11) |
Age (years), mean (SD) | 34.3 (7.6) | 31.6 (7.7) | 35.9 (7.1) | 36.2 (7.4) | 34.30 (7.4) |
Male sex, n (%) | 61 (33.4) | 23 (46.9) | 41 (19.2) | 28 (28.2) | 23 (42.5) |
White, n (%) | 130 (72.2) | 29 (59.2) | 38 (73.1) | 28 (71.8) | 35 (87.5) |
Hispanic/Latino ethnicity, n (%) | 40 (22.2) | 13 (26.5) | 11 (21.2) | 8 (20.5) | 8 (20.0) |
SES Z-score, mean (SD) | 0.0 (1.0) | -0.3 (1.1) | 0.2 (0.9) | 0.0 (1.0) | 0.0 (0.9) |
BMI (kg/m2), mean (SD) | 26.8 (6.4 | 29.2 (8.2) | 26.6 (5.3) | 26.6 (6.0) | 24.5 (4.5) |
Current smoker, n (%) | 12 (6.7) | 3 (6.1) | 5 (9.6) | 4 (10.3) | 0 (0.0) |
Composite physical activity (times per week), mean (SD) | 6.0 (4.4) | 5.3 (4.5) | 5.8 (4.4) | 6.0 (5.0) | 6.9 (3.7) |
Disease duration (years), mean (SD) | 2.2 (1.4) | 2.1 (1.47) | 2.3 (1.4) | 2.4 (1.5) | 1.8 (1.5) |
CIS, n (%) | 19 (10.6) | 5 (10.2) | 5 (9.6) | 4 (10.3) | 5 (12.5) |
High efficacy disease modifying therapy, n (%) |
39 (21.7) | 13 (26.5) | 9 (17.3) | 6 (15.4) | 11 (27.5) |
EDSS, median (IQR) | 1.0 (0.0–1.5) | 1.0 (0.0–1.5) | 1.0 (0.0–1.5) | 1.0 (0.0–1.5) | 1.0 (0.8–1.6) |
BDI-FS, median (IQR) | 2.00 (1.00–4.00) | 2 (1–6) | 2 (1–4) | 2 (0.5–3.5) | 1 (0–3) |
Key MRI variables, mean (SD) * | |||||
Thalamic Volume | 21.1 (1.7) | 20.6 (1.9) | 21.2 (1.7) | 21.6 (1.5) | 21.4 (1.7) |
Lesion volume | 0.4 (1.4) | 0.8 (1.5) | 0.3 (1.4 | 0.3 (1.3) | 0.4 (1.4) |
NAWM FA MD | 0.0 (0.9) | −0.3 (1.0) | 0.2 (0.9) | 0.0 (0.9) | 0.1 (0.9) |
Gray matter volume* | 804.6 (47.8) | 806.7 (54.6) |
799.5 (38.4) |
808.8 (46.1) | 804.3 (52.5) |
Units for volumetric measures are presented as mL. T2 lesion volume was log-transformed to improve normality; NAWM FA MD: Normal appearing white matter fractional anisotropy, mean diffusivity.